2. Inflammation/Immunology

Inflammation/Immunology

Inflammation/Immunology

Related Products

PDF 93.1 MB

The diseases caused by disorders of the immune system fall into two broad categories: immunodeficiency and autoimmunity. Immunotherapy is also often used in the immunosuppressed (such as HIV patients) and people suffering from other immune deficiencies or autoimmune diseases. This includes regulating factors such as IL-2, IL-10, IFN-α. Infection with HIV is characterized not only by development of profound immunodeficiency but also by sustained inflammation and immune activation. Chronic inflammation as a critical driver of immune dysfunction, premature appearance of aging-related diseases, and immune deficiency.

Cat. No. Product Name CAS No. Purity Chemical Structure
  • HY-182628
    CJ-036878 951248-25-2
    CJ-036878 is a NMDAR NR2B subunit antagonist. CJ-036878 is applicable to research related to persistent inflammatory pain and neuropathic pain.
    CJ-036878
  • HY-182629
    CJ-040714 847605-11-2
    CJ-040714 is an ethanedisulfonate hemisalt that can be used for the research of gastroesophageal reflux disease.
    CJ-040714
  • HY-182630
    CJ-14897 377755-95-8
    CJ-14897 is a cytokine production inhibitor, with IC50 values of 0.059 μM and 0.59 μM for IL-1β and TNF-α production, respectively, and an IC50 of 180 μM for leucine uptake. CJ-14897 is isolated from the fermentation broth of the basidiomycete Marasmius strain CL21624.
    CJ-14897
  • HY-182632
    LP-935001 1875037-24-3
    LP-935001 is a Notum carboxylesterase inhibitor with an IC50 of 0.4 nM.LP-935001 prevents palmitoleate group removal from Wnt proteins, restores Wnt/β-catenin signaling.LP-935001 enhances cortical bone thickness in rodent models.LP-935001 can be used for the research of bone loss/nonvertebral fractures.
    LP-935001
  • HY-182636
    MT16-001 1895049-73-6
    MT16-001 is a cell-permeable UCHL1 inhibitor with an IC50 value of 580 nM. MT16-001 also exhibits considerable inhibitory activity against USP30, and shows selectivity for other UCH family deubiquitinases (DUBs) as well as the broader proteome. MT16-001 binds covalently to the cysteine residue at the active site of UCHL1, and forms covalent interactions with ALDH2, ALDH9A1 and GATD3A in intact cells. Meanwhile, as a cytotoxic agent, it displays a steep dose-response curve in human embryonic kidney cells. MT16-001 can be used for research on various cancers, liver fibrosis and pulmonary fibrosis.
    MT16-001
  • HY-182637
    ACT-774312 1809863-68-0
    ACT-774312 is a potent and selective CRTH2 antagonist with an IC50 of 4 nM. ACT-774312 blocks the activity and internalization of the CRTH2 receptor, and inhibits PGD2-induced morphological changes in eosinophils. ACT-774312 can be used in the research of nasal polyps and type 2 inflammatory diseases.
    ACT-774312
  • HY-182640
    SM-11044 142784-65-4
    SM-11044 is a β-adrenoceptor agonist with Ki values of 18.1 μM (β1), 4.1 μM (β2) and 1.3 μM (β3), showing higher binding selectivity for the β3-adrenoceptor. SM-11044 stimulates cAMP accumulation in cells expressing this receptor. SM-11044 mediates ileal relaxation, tracheal relaxation, pulmonary parenchymal relaxation, increased right atrial heart rate and adipocyte lipolysis.
    SM-11044
  • HY-182643
    NO-794 105150-87-6
    NO-794 is a histamine H2 receptor antagonist. NO-794 inhibits gastric acid secretion in pylorus-ligated rats. NO-794 can be used for the research of peptic ulcers.
    NO-794
  • HY-182647
    LY3023703 1415089-24-5
    LY3023703 is an orally active microsomal prostaglandin E synthase-1 (mPGES-1) inhibitor. LY3023703 inhibits the production of PGE2. LY3023703 is applicable to research related to inflammatory diseases and osteoarthritis pain.
    LY3023703
  • HY-182680
    Manoalogue 136440-42-1
    Manoalogue is an irreversible secretory phospholipase A2 (sPLA2) inhibitor. Manoalogue covalently modifies K94 of bee venom phospholipase A2 (bvPLA2) to inactivate the enzyme and shows selective inhibition on bvPLA2. Manoalogue can suppress PLA2-mediated contractions of guinea pig lung pleural strips. Manoalogue is used for sPLA2 mechanism and respiratory physiology research.
    Manoalogue
  • HY-182692
    KMO-IN-1 1953156-92-7
    KMO-IN-1 is a KMO inhibitor with a mean pIC50 of 8.5 against KMO. KMO-IN-1 can be used in the research of acute pancreatitis.
    KMO-IN-1
  • HY-182693
    CPL302-253 2019223-60-8 98%
    CPL302-253 is a PI3Kδ inhibitor with an IC50 of 12.20 nM and a human Kd of 0.85 nM. CPL302-253 functionally regulates PI3Kδ activity, blocks the production of IFNγ, IL-33 and ROS in immune cells, and affects immune function. CPL302-253 blocks the progression of asthma-inducing inflammatory responses in a mouse model of asthma. CPL302-253 can be used for research related to asthma.
    CPL302-253
  • HY-182696
    CGS 24891 134823-10-2
    CGS 24891 is an orally active 5-lipoxygenase (5-LO) inhibitor, with an IC50 value of 0.051 μM in guinea pigs and 0.11 μM in dogs. CGS 24891 inhibits the production of 5-hydroxyeicosatetraenoic acid (5-HETE) and leukotriene B4 (LTB4) from arachidonic acid. CGS 24891 weakly inhibits 12-lipoxygenase (12-LO) with an IC50 of 0.41 μM. CGS 24891 is applicable to research on inflammation and allergic reactions.
    CGS 24891
  • HY-182699
    PROTAC STAT6 degrader-5 3077471-62-3 98%
    PROTAC STAT6 degrader-5 is a PROTAC degrader that selectively targets STAT6. PROTAC STAT6 degrader-5 induces the degradation of STAT6 protein. PROTAC STAT6 degrader-5 can be used in inflammation and cancer research.
    PROTAC STAT6 degrader-5
  • HY-182701
    5-HT3 antagonist-7 149685-89-2
    5-HT3 antagonist-7 (Compound 7e) is a competitive and selective 5-HT3 receptor antagonist. 5-HT3 antagonist-7 inhibits 5-HT-induced contractions in guinea pig ileum and guinea pig thoracic aorta. 5-HT3 antagonist-7 prevents 2-methyl-5-HT-induced vomiting episodes in ferrets.
    5-HT3 antagonist-7
  • HY-182718
    AZD0011-PL 2374807-39-1
    AZD0011-PL is a human arginase 1/ 2 inhibitor with IC50 values of 0.01 μM and 0.02 μM. AZD0011-PL can be used for the researches of cancer, respiratory inflammatory disease.
    AZD0011-PL
  • HY-182724
    PSB-18422 2244978-64-9
    PSB-18422 is a GPR17 agonist, with an EC50 of 0.0279 μM for humans, 0.47 μM for rats, 0.753 μM for mice, and a human Ki of 1.46 μM. PSB-18422 triggers intracellular calcium mobilization via cross-species activation of GPR17. PSB-18422 can be used in the research of allergic bronchial inflammation.
    PSB-18422
  • HY-182735
    BMS-570520 388101-58-4 98%
    BMS-570520 is an orally bioavailable CCR3 antagonist with an IC50 of 1.9 nM against hCCR3 and an IC50 of 1300 nM against hCYP2D6. BMS-570520 inhibits CYP2D6, but shows low activity against off-target G protein-coupled receptors, biogenic amine transporters, and the hERG potassium channel. BMS-570520 regulates chemotaxis, calcium mobilization, and anti-inflammatory pathways. BMS-570520 can be used in research related to asthma, allergic rhinitis, and contact dermatitis.
    BMS-570520
  • HY-182736
    YM-344484 671205-14-4
    YM-344484 is an orally active dual antagonist of chemokine CCR3 receptor and histamine histamine H1 receptor. YM-344484 inhibits ligand-induced Ca2+ influx, chemotaxis of CCR3-expressing cells, histamine-induced Ca2+ influx, increased vascular permeability and eosinophil accumulation. YM-344484 suppresses vascular permeability and inhibits eosinophil infiltration in a mouse asthma model. YM-344484 can be used in research related to asthma, allergic rhinitis and atopic dermatitis.
    YM-344484
  • HY-182750
    ACLY-IN-3
    ACLY-IN-3 is an ATP-citrate lyase (ACLY) inhibitor with an IC50 of 0.036 μM and a target Kd of 0.54 μM. ACLY-IN-3 interacts with the allosteric binding site of ACLY to inhibit its activity. ACLY-IN-3 exhibits excellent lipid-lowering effects and alleviates hepatic inflammation and liver fibrosis. ACLY-IN-3 can be used for the research of metabolic dysfunction-associated steatohepatitis.
    ACLY-IN-3
Cat. No. Product Name / Synonyms Application Reactivity